Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
Mahmoud MohammadiNikki S IJzermanDide den HollanderRoos F BleckmanAstrid W OostenIngrid M E DesarAn K L ReynersNeeltje SteeghsHans GelderblomPublished in: Targeted oncology (2023)
This study provides an update on outcomes of imatinib in the treatment of advanced GIST patients and demonstrates improved clinical outcomes since the first randomized studies of imatinib 2 decades ago. Furthermore, these results represent outcomes in real-world clinical practice and can serve as a reference when evaluating effectiveness of imatinib in patients with advanced GIST.
Keyphrases
- chronic myeloid leukemia
- end stage renal disease
- clinical practice
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- open label
- double blind
- prognostic factors
- type diabetes
- adipose tissue
- patient reported outcomes
- clinical trial
- phase iii
- glycemic control
- skeletal muscle
- phase ii
- machine learning
- data analysis
- study protocol